NAO.VNS NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy
- Coordinator
- Synergia Medical, Belgium
- Runs
- 1 March 2023 to 31 August 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €4.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190198268
What the project is doing
In the project's own words, from its summary on CORDIS.
19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive. We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator.
We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy. Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals.
We expect to generate €89M by 2028 selling in the EU/US.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Synergia Medical | Mont-Saint-Guibert | Belgium | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI